The recent review dismissing Gerson therapy as useless or worse for the treatment of cancer was published before this landmark study came out: a head-to-head test of a Gerson-style regime, versus the standard chemotherapy agent gemcitabine, for pancreatic cancer—one of the deadliest of all malignancies.